StockNews.com began coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a research note issued to investors on Monday. The firm set a “sell” rating on the biotechnology company’s stock.
Several other equities research analysts have also issued reports on GLYC. HC Wainwright reiterated a “neutral” rating on shares of GlycoMimetics in a research report on Tuesday, June 4th. Capital One Financial cut shares of GlycoMimetics from an “overweight” rating to an “equal weight” rating in a research report on Monday, May 6th.
Check Out Our Latest Research Report on GLYC
GlycoMimetics Stock Performance
GlycoMimetics (NASDAQ:GLYC – Get Free Report) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sell-side analysts predict that GlycoMimetics will post -0.62 earnings per share for the current year.
Insider Activity
In other news, insider Edwin Rock bought 190,000 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was bought at an average price of $0.25 per share, for a total transaction of $47,500.00. Following the transaction, the insider now directly owns 565,403 shares of the company’s stock, valued at approximately $141,350.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 8.70% of the company’s stock.
Hedge Funds Weigh In On GlycoMimetics
A number of large investors have recently bought and sold shares of GLYC. Advisor OS LLC bought a new position in shares of GlycoMimetics in the fourth quarter worth approximately $238,000. MJP Associates Inc. ADV bought a new position in shares of GlycoMimetics during the fourth quarter valued at about $238,000. Finally, Vanguard Group Inc. boosted its holdings in shares of GlycoMimetics by 14.0% during the first quarter. Vanguard Group Inc. now owns 2,761,981 shares of the biotechnology company’s stock worth $8,286,000 after purchasing an additional 340,112 shares during the period. 75.19% of the stock is owned by hedge funds and other institutional investors.
GlycoMimetics Company Profile
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
See Also
- Five stocks we like better than GlycoMimetics
- Stock Market Upgrades: What Are They?
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.